CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
54.00
+0.48 (0.90%)
Aug 10, 2026, 11:38 AM EDT - Market open
CRISPR Therapeutics AG Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 13.39 | 3.51 | 37.31 | 371.21 | 1.2 | 914.96 | |
Revenue Growth | -64.80% | -90.59% | -89.95% | 30885.48% | -99.87% | 127154.94% |
Gross Profit | 13.39 | 3.51 | 37.31 | 371.21 | 1.2 | 914.96 |
Selling, General & Admin | 70.07 | 73.54 | 72.98 | 76.16 | 102.46 | 99.69 |
Research & Development | 280.63 | 381.06 | 310.24 | 387.33 | 461.65 | 340.57 |
Other Operating Expenses | 197.04 | 213.48 | 120.67 | 130.25 | 110.25 | 101.18 |
Total Operating Expenses | 547.73 | 668.08 | 503.88 | 593.74 | 674.36 | 541.44 |
Operating Income | -534.34 | -664.57 | -466.57 | -222.54 | -673.16 | 373.53 |
Total Non-Operating Income (Expense) | 86.23 | 86.61 | 103.9 | 71.82 | - | - |
Pretax Income | -448.11 | -577.97 | -362.67 | -150.72 | -650.5 | 379.53 |
Provision for Income Taxes | 3.03 | 3.63 | 3.59 | 2.89 | -0.33 | 1.87 |
Net Income | -451.14 | -581.6 | -366.25 | -153.61 | -650.18 | 377.66 |
Net Income to Common | -451.14 | -581.6 | -366.25 | -153.61 | -650.18 | 377.66 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 95 | 90 | 84 | 79 | 78 | 76 |
Shares Outstanding (Diluted) | 95 | 90 | 84 | 79 | 78 | 80 |
Shares Change | 10.31% | 6.60% | 6.49% | 1.90% | -3.29% | 21.90% |
EPS (Basic) | -4.76 | -6.47 | -4.34 | -1.94 | -8.36 | 4.97 |
EPS (Diluted) | -4.76 | -6.47 | -4.34 | -1.94 | -8.36 | 4.70 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -371.33 | -345.93 | -144.68 | -269.85 | -532.93 | 457.27 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Per Share | -3.92 | -3.85 | -1.71 | -3.41 | -6.85 | 5.69 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -3989.99% | -18933.60% | -1250.38% | -59.95% | -56190.40% | 40.82% |
Profit Margin | -3368.72% | -16569.80% | -981.54% | -41.38% | -54271.70% | 41.28% |
FCF Margin | -2772.74% | -9855.50% | -387.72% | -72.69% | -44484.90% | 49.98% |
EBITDA | -515.65 | -645.09 | -447.31 | -202.7 | -648.99 | 391.48 |
EBITDA Margin | -3850.41% | -18378.70% | -1198.76% | -54.61% | -54172.70% | 42.79% |
EBIT | -534.34 | -664.57 | -466.57 | -222.54 | -673.16 | 373.53 |
EBIT Margin | -3989.99% | -18933.60% | -1250.38% | -59.95% | -56190.40% | 40.82% |
Effective Tax Rate | -0.68% | -0.63% | -0.99% | -1.92% | 0.05% | 0.49% |